XML 86 R61.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Summary of Quarterly Results of Operations (Detail) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Quarterly Financial Information Disclosure [Abstract]                      
Total revenues $ 244,010 $ 222,094 $ 183,580 $ 138,403 $ 131,492 $ 151,757 $ 96,905 $ 71,086 $ 788,087 $ 451,240 $ 161,626
Total operating expenses 195,289 [1] 131,996 [1] 149,119 [1] 239,400 [1] 109,621 97,434 98,757 108,533 715,804 414,345 292,987
Net (loss) income $ 34,000 [1] $ 53,789 [1] $ 51,338 [1] $ (102,115) [1] $ 18,078 $ 50,764 $ (5,913) $ (41,818) $ 37,012 $ 21,111 $ (142,542)
Net (loss) income per share, basic $ 0.37 [1] $ 0.59 [1] $ 0.56 [1] $ (1.12) [1] $ 0.20 $ 0.56 $ (0.07) $ (0.47) $ 0.40 $ 0.23 $ (1.62)
Net (loss) income per share, diluted $ 0.35 [1] $ 0.56 [1] $ 0.54 [1] $ (1.12) [1] $ 0.19 $ 0.52 $ (0.07) $ (0.47) $ 0.39 $ 0.22 $ (1.62)
Weighted average common shares outstanding, basic 92,182,000 91,859,000 91,389,000 91,056,000 90,742,000 90,555,000 90,100,000 89,526,000 91,627,000 90,235,000 88,089,000
Weighted average common shares outstanding, diluted 97,229,000 96,074,000 94,779,000 91,056,000 95,724,000 96,798,000 90,100,000 89,526,000 95,732,000 95,386,000 88,089,000
[1] In connection with the payment of the upfront fee pursuant to our collaboration and license agreement with Voyager, we recorded a charge of $113.1 million, accounted for as IPR&D, in the first quarter of 2019. In the second quarter of 2019, we entered into an amendment to the collaboration and license agreement with Voyager, pursuant to which we paid Voyager $5.0 million upfront, accounted for as IPR&D, to obtain outside the U.S. rights to the Friedreich’s ataxia program. In connection with the payment of the upfront fee pursuant to our collaboration with Xenon, we recorded a charge of $36.2 million, accounted for as IPR&D, in the fourth quarter of 2019.